Updated

A clinical trial for DIPG, a deadly childhood brain cancer with limited treatment options, was delayed due to federal research funding cuts, costing patients valuable time in their fight against the disease. The setback underscores the real-world stakes of reductions in federal research funding and highlights how budget constraints ripple through the medical research ecosystem.